Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 4 2Phase 3 2Phase 1/2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-squamous Non-small-cell Lung Cancer 1

Interventions

Dexamethasone 8Oxycodone 6Epoetin Alfa 5Propofol 4Palonosetron 4Meropenem 4Zoledronic Acid 3Vancomycin 3Sevoflurane 3Ondansetron 3Naloxone 3Everolimus 3Ciprofloxacin 3Cholecalciferol 3Ceftazidime 3Cefepime 3Calcium Dobesilate 3Bevacizumab 3Aspirin 3Aprepitant 3peginterferon alfa-2a 2edoxaban 2apixaban 2apatinib 2Vitamin B 12 2Vincristine 2Tobacco Use Cessation Devices 2Teicoplanin 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms × apatinib × Clear all
NCT03475589 2020-05-12

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Sun Yat-sen University

Phase 4 Unknown
217 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT03384511 2018-02-20

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Shandong Cancer Hospital and Institute

Phase 4 Completed
38 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡